The ADC trastuzumab deruxtecan is the only HER2-targeting agent that has been approved by the FDA for the treatment of patients with HER2-mutated NSCLC who have previously received other systemic therapies [159]. Here, ERBB2 is linked to non-small cell lung carcinoma.